Login / Signup

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.

Anne-Kristina MercierMikael SunnåkerSebastian UeckertTadeusz PawlikEmilia HenricsonOleksandr MolodetskyiGordon C LawVictoria E R ParkerJan Oscarsson
Published in: Clinical pharmacokinetics (2023)
ClinicalTrials.gov identifier: NCT05112419.
Keyphrases
  • high intensity
  • open label
  • locally advanced
  • squamous cell carcinoma
  • radiation therapy
  • rectal cancer